Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.
Identifieur interne : 000185 ( PubMed/Corpus ); précédent : 000184; suivant : 000186Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.
Auteurs : Christel Renoux ; Sophie Dell'Aniello ; Paul Khairy ; Connie Marras ; Shawn Bugden ; Tanvir Chowdhury Turin ; Lucie Blais ; Hala Tamim ; Charity Evans ; Russell Steele ; Colin Dormuth ; Pierre ErnstSource :
- British journal of clinical pharmacology [ 1365-2125 ] ; 2016.
Abstract
Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson's disease (PD). Concerns have been raised regarding an increased risk of ventricular tachyarrhythmia and sudden cardiac death (VT/SCD) associated with domperidone in the general population. However, the risk in PD is unknown.
DOI: 10.1111/bcp.12964
PubMed: 27062307
Links to Exploration step
pubmed:27062307Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.</title><author><name sortKey="Renoux, Christel" sort="Renoux, Christel" uniqKey="Renoux C" first="Christel" last="Renoux">Christel Renoux</name><affiliation><nlm:affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Dell Aniello, Sophie" sort="Dell Aniello, Sophie" uniqKey="Dell Aniello S" first="Sophie" last="Dell'Aniello">Sophie Dell'Aniello</name><affiliation><nlm:affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Khairy, Paul" sort="Khairy, Paul" uniqKey="Khairy P" first="Paul" last="Khairy">Paul Khairy</name><affiliation><nlm:affiliation>Montreal Heart Institute Adult Congenital Center, Université de Montréal, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital and the Edmond J. Safra Program in Parkinson's Disease Research, University of Toronto, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Bugden, Shawn" sort="Bugden, Shawn" uniqKey="Bugden S" first="Shawn" last="Bugden">Shawn Bugden</name><affiliation><nlm:affiliation>Faculty of Health Sciences, College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Turin, Tanvir Chowdhury" sort="Turin, Tanvir Chowdhury" uniqKey="Turin T" first="Tanvir Chowdhury" last="Turin">Tanvir Chowdhury Turin</name><affiliation><nlm:affiliation>Department of Family Medicine, Cumming School of Medicine, University of Calgary, Health Sciences Centre, Calgary, AB, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Blais, Lucie" sort="Blais, Lucie" uniqKey="Blais L" first="Lucie" last="Blais">Lucie Blais</name><affiliation><nlm:affiliation>Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Tamim, Hala" sort="Tamim, Hala" uniqKey="Tamim H" first="Hala" last="Tamim">Hala Tamim</name><affiliation><nlm:affiliation>School of Kinesiology and Health Science, York University, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Evans, Charity" sort="Evans, Charity" uniqKey="Evans C" first="Charity" last="Evans">Charity Evans</name><affiliation><nlm:affiliation>College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Steele, Russell" sort="Steele, Russell" uniqKey="Steele R" first="Russell" last="Steele">Russell Steele</name><affiliation><nlm:affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Dormuth, Colin" sort="Dormuth, Colin" uniqKey="Dormuth C" first="Colin" last="Dormuth">Colin Dormuth</name><affiliation><nlm:affiliation>Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ernst, Pierre" sort="Ernst, Pierre" uniqKey="Ernst P" first="Pierre" last="Ernst">Pierre Ernst</name><affiliation><nlm:affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27062307</idno><idno type="pmid">27062307</idno><idno type="doi">10.1111/bcp.12964</idno><idno type="wicri:Area/PubMed/Corpus">000185</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000185</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.</title><author><name sortKey="Renoux, Christel" sort="Renoux, Christel" uniqKey="Renoux C" first="Christel" last="Renoux">Christel Renoux</name><affiliation><nlm:affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Dell Aniello, Sophie" sort="Dell Aniello, Sophie" uniqKey="Dell Aniello S" first="Sophie" last="Dell'Aniello">Sophie Dell'Aniello</name><affiliation><nlm:affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Khairy, Paul" sort="Khairy, Paul" uniqKey="Khairy P" first="Paul" last="Khairy">Paul Khairy</name><affiliation><nlm:affiliation>Montreal Heart Institute Adult Congenital Center, Université de Montréal, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital and the Edmond J. Safra Program in Parkinson's Disease Research, University of Toronto, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Bugden, Shawn" sort="Bugden, Shawn" uniqKey="Bugden S" first="Shawn" last="Bugden">Shawn Bugden</name><affiliation><nlm:affiliation>Faculty of Health Sciences, College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Turin, Tanvir Chowdhury" sort="Turin, Tanvir Chowdhury" uniqKey="Turin T" first="Tanvir Chowdhury" last="Turin">Tanvir Chowdhury Turin</name><affiliation><nlm:affiliation>Department of Family Medicine, Cumming School of Medicine, University of Calgary, Health Sciences Centre, Calgary, AB, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Blais, Lucie" sort="Blais, Lucie" uniqKey="Blais L" first="Lucie" last="Blais">Lucie Blais</name><affiliation><nlm:affiliation>Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Tamim, Hala" sort="Tamim, Hala" uniqKey="Tamim H" first="Hala" last="Tamim">Hala Tamim</name><affiliation><nlm:affiliation>School of Kinesiology and Health Science, York University, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Evans, Charity" sort="Evans, Charity" uniqKey="Evans C" first="Charity" last="Evans">Charity Evans</name><affiliation><nlm:affiliation>College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Steele, Russell" sort="Steele, Russell" uniqKey="Steele R" first="Russell" last="Steele">Russell Steele</name><affiliation><nlm:affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Dormuth, Colin" sort="Dormuth, Colin" uniqKey="Dormuth C" first="Colin" last="Dormuth">Colin Dormuth</name><affiliation><nlm:affiliation>Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ernst, Pierre" sort="Ernst, Pierre" uniqKey="Ernst P" first="Pierre" last="Ernst">Pierre Ernst</name><affiliation><nlm:affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</nlm:affiliation></affiliation></author></analytic><series><title level="j">British journal of clinical pharmacology</title><idno type="eISSN">1365-2125</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson's disease (PD). Concerns have been raised regarding an increased risk of ventricular tachyarrhythmia and sudden cardiac death (VT/SCD) associated with domperidone in the general population. However, the risk in PD is unknown.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27062307</PMID><DateCreated><Year>2016</Year><Month>07</Month><Day>18</Day></DateCreated><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2125</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>British journal of clinical pharmacology</Title><ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>461-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.12964</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson's disease (PD). Concerns have been raised regarding an increased risk of ventricular tachyarrhythmia and sudden cardiac death (VT/SCD) associated with domperidone in the general population. However, the risk in PD is unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a multicentre retrospective cohort study using administrative databases from seven Canadian provinces and the UK Clinical Practice Research Datalink. Using a nested case-control analysis, we estimated the rate ratios (RRs) of VT/SCD associated with domperidone use compared to no use in patients newly-diagnosed with PD. VT/SCD events were identified using administrative medical records and vital statistics with a manual review of all potential cases. Meta-analytic methods were used to estimate overall effects across sites.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 214 962 patients with PD, 2907 cases of VT/SCD were identified during 886 581 person-years of follow-up (incidence rate 3.28 per 1000 persons per year). Current use of domperidone was associated with a non-statistically significant 22% increased risk of VT/SCD (RR 1.22; 95% CI 0.99-1.50) compared with no use. The risk was significantly elevated in those with a history of cardiovascular disease (RR 1.38; 95% CI 1.07-1.78), but not in those without (RR 1.21; 95% CI 0.81-1.81). Dose and duration of use did not affect the magnitude of the risk.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Domperidone use may increase the risk of VT/SCD in patients with PD, particularly those with a history of cardiovascular disease. This risk may be underestimated because of imprecision in identifying VT/SCD events.</AbstractText><CopyrightInformation>© 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Renoux</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, McGill University, Montréal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dell'Aniello</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khairy</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Montreal Heart Institute Adult Congenital Center, Université de Montréal, Montréal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marras</LastName><ForeName>Connie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital and the Edmond J. Safra Program in Parkinson's Disease Research, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bugden</LastName><ForeName>Shawn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turin</LastName><ForeName>Tanvir Chowdhury</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Cumming School of Medicine, University of Calgary, Health Sciences Centre, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blais</LastName><ForeName>Lucie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamim</LastName><ForeName>Hala</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Kinesiology and Health Science, York University, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Charity</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steele</LastName><ForeName>Russell</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, McGill University, Montréal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dormuth</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Pulmonary Division, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Canadian Network for Observational Drug Effect Studies (CNODES) investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Clin Pharmacol</MedlineTA><NlmUniqueID>7503323</NlmUniqueID><ISSNLinking>0306-5251</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):34-41</RefSource><PMID Version="1">22109939</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1994 Jun 30;330(26):1852-7</RefSource><PMID Version="1">8196728</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2004 Sep 15;44(6):1268-75</RefSource><PMID Version="1">15364331</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Sci. 2002 Jul 15;199(1-2):31-7</RefSource><PMID Version="1">12084439</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2000 Oct 17;102(16):1883-5</RefSource><PMID Version="1">11034933</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Saf. 2010 Nov 1;33(11):1003-14</RefSource><PMID Version="1">20925438</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2015 Aug;24(8):841-8</RefSource><PMID Version="1">26098410</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):881-8</RefSource><PMID Version="1">20652862</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2013 Nov;19(11):1000-3</RefSource><PMID Version="1">23871463</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 2007 Feb;63(2):216-23</RefSource><PMID Version="1">16869820</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2014 Apr 29;82(17 ):1514-20</RefSource><PMID Version="1">24682965</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Drug Saf. 2013 Feb;8(1):63-8</RefSource><PMID Version="1">23656449</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Open Med. 2012 Oct 30;6(4):e134-40</RefSource><PMID Version="1">23687528</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am Heart J. 2003 Oct;146(4):581-90</RefSource><PMID Version="1">14564310</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2013 Jun;19(6):586-9</RefSource><PMID Version="1">23522959</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2005 Oct;26(19):2007-12</RefSource><PMID Version="1">15888497</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2008 Aug 1;168(3):329-35</RefSource><PMID Version="1">18515793</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2010 Feb 05;340:c249</RefSource><PMID Version="1">20139216</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 2009 Nov;68(5):743-51</RefSource><PMID Version="1">19916999</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am Heart J. 2015 Apr;169(4):508-14</RefSource><PMID Version="1">25819857</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):563-72</RefSource><PMID Version="1">20029823</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2006 Jun;5(6):525-35</RefSource><PMID Version="1">16713924</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 2016 Aug;82(2):461-72</RefSource><PMID Version="1">27062307</PMID></CommentsCorrections></CommentsCorrectionsList><OtherID Source="NLM">PMC4972162 [Available on 08/01/17]</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">domperidone</Keyword><Keyword MajorTopicYN="N">sudden cardiac death</Keyword><Keyword MajorTopicYN="N">ventricular arrhythmia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>03</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>08</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27062307</ArticleId><ArticleId IdType="doi">10.1111/bcp.12964</ArticleId><ArticleId IdType="pmc">PMC4972162</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000185 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000185 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27062307
|texte= Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27062307" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |